- Home
- ENPH vs DNTH Comparison
ENPH vs DNTH Comparison
Compare ENPH & DNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ENPH | DNTH |
|---|---|---|
| Founded | 2006 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.5B | 4.6B |
| IPO Year | 2011 | 2018 |
Fundamental Metrics
Financial Performance| Metric | ENPH | DNTH |
|---|---|---|
| Price | $63.74 | $89.45 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 23 | 13 |
| Target Price | $41.30 | ★ $121.00 |
| AVG Volume (30 Days) | ★ 8.8M | 448.7K |
| Earning Date | 04-28-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 72.00 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,472,985,000.00 | $2,036,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $9.81 | $29.48 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 10.72 | N/A |
| 52 Week Low | $25.78 | $16.77 |
| 52 Week High | $73.74 | $96.50 |
Technical Indicators
Market Signals| Indicator | ENPH | DNTH |
|---|---|---|
| Relative Strength Index (RSI) | 68.18 | 57.31 |
| Support Level | $32.08 | $81.16 |
| Resistance Level | N/A | $96.50 |
| Average True Range (ATR) | 5.97 | 4.40 |
| MACD | 1.87 | 0.35 |
| Stochastic Oscillator | 74.49 | 82.25 |
Price Performance
Historical ComparisonAbout ENPH Enphase Energy Inc.
Enphase Energy is a global energy technology company. It delivers smart, easy-to-use solutions that manage solar generation, storage, and communication on one platform. The company's microinverter technology primarily serves the rooftop solar market and produces a fully integrated solar-plus-storage solution. Enphase derives a majority of revenue from the United States.
About DNTH Dianthus Therapeutics Inc.
Dianthus Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing potentially best-in-class therapies for patients with severe autoimmune diseases. The company operates as a single segment and has one reportable segment, focusing on creating next-generation treatments to revolutionize the management of severe autoimmune conditions. The team comprises experienced biotech and pharma executives. The pipeline includes the potential of Claseprubart, a next-generation complement therapeutic.